AddedRisk Factors
Acts of God, such as major weather disturbances or other force majeure events, could disrupt our business.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RemovedRisk Factors
Our contracts generally use certain published benchmarks to establish pricing for the reimbursement of prescription medications we dispense. These benchmarks include AWP, wholesale acquisition cost, ASP and average manufacturer price. Many of our contracts utilize the AWP benchmark. Publication of the AWP benchmark was expected to cease in 2011 as a result of the settlement of class-action lawsuits brought against First Databank and Medi-Span, third-party publishers of various pricing benchmarks. However, Medi-Span continues to publish the AWP benchmark and has indicated that it will continue to do so until a new benchmark is widely accepted. Several industry participants have explored establishing a new benchmark but there is not currently a viable generally accepted alternative to the AWP benchmark. Without a suitable pricing benchmark in place, many of our contracts may need to be modified, which could potentially change the economic structure of our agreements.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
Failure to develop new services or adapt to changes and trends within the healthcare industry may adversely affect our business.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
We are subject to pricing pressures and other risks involved with Third-Party Payers.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
We cannot predict the impact of changing requirements on compounding pharmacies.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
We may issue shares of preferred stock in the future, which could make it difficult for another company to acquire us or could otherwise adversely affect holders of our common stock, which could depress the price of our common stock.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
Our third amended and restated certificate of incorporation authorizes us to issue one or more series of preferred stock. Our Board of Directors has the authority to determine the preferences, limitations and relative rights of the shares of preferred stock and to fix the number of shares constituting any series and the designation of such series, without any further vote or action by our stockholders. Our preferred stock could be issued with voting, liquidation, dividend and other rights superior to the rights of our common stock. The potential issuance of preferred stock may delay or prevent a change in control, discouraging bids for our common stock at a premium to the market price, and materially and adversely affecting the market price and the voting and other rights of the holders of our common stock.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
Acquisitions, strategic investments and strategic relationships involve certain risks.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
Our business is dependent on the services provided by third-party information technology vendors.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
We use, and may continue to expand our use of, machine learning and artificial intelligence (“AI”) technologies to deliver our services and operate our business.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RewordedRisk Factors
If personal personally identifiable information or protected health information is improperly accessed, tampered with or disclosed as a result of a security breach, we may incur significant costs to notify, and mitigate potential harm to the affected individuals, and we may be subject to sanctions and civil or criminal penalties if we are found to be in violation of the privacy or security rules under HIPAA or other federal or state laws protecting confidential personal information. individuals.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
If personal information or protected health information is improperly accessed, tampered with or disclosed as a result of a security breach, we may incur significant costs to notify, and mitigate potential harm to the affected individuals, and we We may be subject to sanctions and civil or criminal penalties if we are found to be in violation of the privacy or security rules under HIPAA or other federal or state laws protecting confidential personal information.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
These requirements included a 10-year timeline culminating In addition, the Company believes it complies in all material respects with the building of "an Drug Supply Chain Security Act (“DSCSA”), which includes an electronic, interoperable system to identify and trace certain prescription drugs as they are distributed in the United States.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Increases in interest rates may directly impact the amount of interest we are required to pay pay, as our First Lien Term Loan has an applicable interest rate of Term SOFR plus 1.75%, and reduce earnings accordingly.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
We maintain our information technology systems with safeguards against cyber-attacks including passive intrusion protection, prevention and detection, firewalls and virus detection software. continuous monitoring of our environment for viruses and malware.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Cybersecurity refers to the combination of technologies, processes and procedures established to protect information technology systems and data from unauthorized access, attack, or damage. damage as well as the development of a company culture of security and data protection.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Despite our indebtedness, we We may still incur significantly more additional debt, which could exacerbate increase the risks associated with our substantial leverage.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although we have taken steps to protect the security of our information technology systems and the data maintained in those systems, it is possible that our safety and security measures will not prevent the systems’ improper functioning or damage or the improper access or disclosure of personal health information or personally identifiable information such as in the event of cyber-attacks. a cyber-attack or employee error or misuse of the system.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
The Center for Medicare & Medicaid Services (“CMS”) CMS began imposing a 2% reduction on Medicare claims on April 1, 2013.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Most recently, the Inflation Reduction Act of 2022 (the “IRA”) granted CMS the authority to negotiate drug prices under Medicare Part D, with price controls taking effect in 2026. D.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
The (“DQSA”) DQSA amended the Federal Drug & Cosmetic Act (“FDCA”) FDCA to grant the FDA additional authority to regulate and monitor the manufacturing of compounded pharmaceutical drugs.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
As a result of operating in the home infusion industry, our business is subject to inherent risk of claims, losses and potential lawsuits alleging medical professional liability incidents involving our employees that are likely to occur in a patient’s home. home or alternate site.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Our revenue and profitability will could decline if the pharmaceutical industry undergoes certain changes, including limiting or discontinuing research, development, production and marketing of the pharmaceuticals that are compatible with the services we provide.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Federal actions and legislation may could reduce reimbursement rates from governmental payers and adversely affect our results of operations.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
In the absence of such cash flow and resources, we could face substantial liquidity problems and might be required to sell material assets or operations to attempt to meet our debt service obligations.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Option Care Health and its wholly-owned subsidiaries provide infusion therapy and other ancillary healthcare services through a national network of 196 locations around the United States. Our national footprint enables us to collaborate with health systems and national payers to provide high quality care at an appropriate cost in a comfortable setting. We have established key relationships that allow us access to local resources to ensure responsiveness to our patients’ needs. At the center of everything we do is the patient. This is the driving force behind all of our actions and the partnerships that we have broadly across the healthcare ecosystem.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Other, Net. Other (expense) income primarily includes activity related to non-operating income and expenses.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
The change in other, net during the year ended December 31, 2025 was primarily attributable to accruals for an abandoned or unclaimed property voluntary disclosure agreement program related to the pre-merger operations of BioScrip, Inc. (“BioScrip”), which was entered into by BioScrip prior to its merger with the Company in 2019. As of December 31, 2025, the matters related to this program are ongoing. Additionally, the change in other, net was attributable to the $4.7 million loss on extinguishment of debt from the Company’s debt refinancing during the year ended December 31, 2025 with no comparable activity during the year ended December 31, 2024.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
The change in net income was attributable to the factors described in the above sections.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
The change in cash provided by operating activities during the year ended December 31, 2025 was primarily due to increases in inventories due to strategic purchases and a focus on maximizing the impact from volume based rebates and prompt pay purchase discounts. The change was also largely related to an increase in accounts receivable driven by revenue growth. The change in cash provided by operating activities for the year ended December 31, 2024 was largely driven by an increase in accounts payable due to timing of strategic purchases in inventories ahead of expected future price increases on certain drugs.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RemovedMD&A
Option Care Health and its wholly-owned subsidiaries provide infusion therapy and other ancillary healthcare services through a national network of 185 locations around the United States. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other non-hospital settings. Our services are provided in coordination with, and under the direction of, the patient’s physician. Our multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to each patient’s specific needs. We provide home infusion services consisting of anti-infectives, nutrition support, therapies for neurological disorders and chronic inflammatory disorders, immunoglobulin therapy, and other therapies for chronic and acute conditions. The Company operates in one segment, infusion services.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
As previously disclosed, on February 21, 2024, Change Healthcare, a subsidiary of UnitedHealth Group, experienced an incident in which a cybersecurity threat actor gained access to some of its information technology systems (“Change Healthcare Cybersecurity Incident”). Since the time of the system disruption, Option Care Health has worked continuously to find alternative processes to help maintain patient care and overall operations.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
As of December 31, 2024, the Company has not identified any compromise or unauthorized access of its systems or networks due to this third party incident. As of the end of the second quarter of 2024, the Company reconnected to key applications maintained by Change Healthcare and as of the end of the fourth quarter of 2024, the Company has fully recovered.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
During the fourth quarter of 2024, the Company did not experience a material financial impact from the Change Healthcare Cybersecurity Incident on the financial results as reported. The Company continues to maintain strong liquidity and, having resumed submission of all claims to payers, has determined that the Change Healthcare Cybersecurity Incident did not materially impact the Company, including its business operations, financial condition or results of operations.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
Other, Net. During the year ended December 31, 2024, other income (expense) primarily includes activity related to non-operating income and expenses. During the year ended December 31, 2023, other income (expense) primarily includes the termination fee, net of merger-related expenses, received on behalf of Amedisys, Inc. (“Amedisys”). On May 3, 2023, the Company entered into a definitive merger agreement (the “Amedisys Merger Agreement”) with Amedisys, a leading provider of healthcare in home health and hospice settings. On June 26, 2023, the Company entered into an agreement to terminate the Amedisys Merger Agreement (the “Mutual Termination Agreement”). Under the terms of the Mutual Termination Agreement, the Company received a payment of $106.0 million in cash on behalf of Amedisys (the “Termination Fee”).
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
The decrease in other, net during the year ended December 31, 2024 was due to the $106.0 million payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses during the year ended December 31, 2023. There was no comparable activity during the year ended December 31, 2024.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
The change in net income for the year ended December 31, 2024 was attributable to the $106.0 million payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses during the year ended December 31, 2023. There was no comparable activity during the year ended December 31, 2024.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
Year Ended December 31, 2024 2023 Variance (in thousands) Net cash provided by operating activities $ 323,392 $ 371,295 $ (47,903) Net cash used in investing activities (36,470) (56,506) 20,036 Net cash used in financing activities (218,206) (265,126) 46,920 Net increase in cash and cash equivalents 68,716 49,663 19,053 Cash and cash equivalents - beginning of period 343,849 294,186 49,663 Cash and cash equivalents - end of period $ 412,565 $ 343,849 $ 68,716
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
The decrease in cash provided by operating activities during the year ended December 31, 2024 was primarily due to the $106.0 million payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses during the year ended December 31, 2023, changes in accounts receivable and accrued compensation and employee benefits. Additionally, changes in accounts payable and inventory were driven by organic growth in the Company as well as strategic supply chain purchases.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RewordedMD&A
The increase in selling, Selling, general and administrative expenses during the year ended December 31, 2024 was primarily due to an increase in salaries, benefits, and general costs to support the business; however, these expenses have declined as a percentage of revenue to 12.1% for the year ended December 31, 2025 compared to 12.6% for the year ended December 31, 2024 compared to 14.1% for the year ended December 31, 2023, 2024, due to the Company’s focus on leveraging existing infrastructure to control spending.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Under the Third Amendment, interest Interest on the First Lien Term Loan is payable monthly on either (i) the SOFR (with a floor of 0.50% per annum) plus an applicable margin of 2.25% 1.75% for Term SOFR Loans (as such term is defined in the Third Amendment); Loans; or (ii) a base rate determined in accordance with the Third Amendment, rate, plus 1.25% 0.75% for Base Rate Loans (as such term is defined in the Third Amendment). Loans.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
The Revolver Facility matures on the date that is the earlier of (i) December 7, 2028 September 22, 2030 and (ii) the date that is 91 days prior to the stated maturity date applicable to the Senior Notes to the extent any Term B Loans. amount of the Senior Notes remains unpaid and outstanding as of the date that is 91 days prior to the stated maturity date applicable to the Senior Notes.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease in gross profit margin was primarily due to the launch of mix, including certain new higher cost therapies included within chronic growth (including rare and orphan therapies) and to the same comparable impact of as well as biosimilar adoption, partially offset by certain temporary favorable procurement dynamics mitigation efforts executed in the prior year that did not continue into 2024. first quarter of 2025.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Net comprehensive income decreased to $200.6 million for the year ended December 31, 2025, compared to net comprehensive income of $207.9 million for the year ended December 31, 2024, compared to net comprehensive income of $260.9 million for the year ended December 31, 2023, primarily as a result of the changes factors described in net income discussed above. the above sections.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
The income tax expense for the year ended December 31, 2023 2025 includes $21.8 million of tax expense related to the Termination Fee received, under the terms of the Mutual Termination Agreement, net of merger-related expenses, and the release of $5.8 $0.4 million of state valuation allowance allowance, compared to a $2.2 million release in September 2023. 2024.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Our business strategy includes the strategic deployment of capital to pursue internal investments in resources, infrastructure, and technologies to support future growth, the pursuit of strategic tuck-in and adjacent acquisitions that complement our existing operations. operations and the pursuit of share repurchases.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in cost of revenue was primarily driven by the growth in revenue, revenue and therapy mix, and acute drug supply chain disruption, as well as the comparable impact of certain temporary favorable therapy procurement dynamics in the prior year. mix.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
The Second Amendment, among other things, Company’s Revolver Facility provides for revolving credit commitments by the applicable Revolving Credit Lenders in an aggregate amount of borrowings up to $400.0 million (the “Revolver Facility”) pursuant to which such lenders have agreed to make Revolving Credit Loans to the Company.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease increase in interest expense, net during the year ended December 31, 2024 2025 was primarily attributable to additional less interest income generated from our cash and cash equivalents, equivalents due to lower interest rates, partially offset by an increase a decrease in the interest rate on the Company’s First Lien Term Loan principal balance, Loan, compared to the year ended December 31, 2023. 2024.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
The variance in the Company’s effective tax rate of 26.6% and 25.3% for the year years ended December 31, 2025 and 2024, respectively, compared to the federal statutory rate of 21%, as well as year-over-year changes, was also primarily attributable to the inclusion of state taxes, taxes in multiple jurisdictions, various non-deductible expenses, and a change changes in state valuation allowance.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Change in unrealized (loss) gain on cash flow hedges, net of income tax benefit (expense) (6,941) (3,931) (6,181) 2,250 (36.4)% (3,010) 76.6% Other comprehensive (loss) income (6,941) (3,931) (6,181) 2,250 (36.4)% (3,010) 76.6% Net comprehensive income $ 200,644 $ 207,892 $ 260,909 $ (53,017) (20.3)% (7,248) (3.5)%
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new